Nano-X Imaging (NNOX) Net Income towards Common Stockholders (2019 - 2026)
Nano-X Imaging (NNOX) posted quarterly Net Income towards Common Stockholders of -$14.1 million for Q1 2026, down 5.23% year-on-year from -$14.9 million in Q1 2025, and up 61.61% on a QoQ basis from -$36.8 million in Q4 2025.
Nano-X Imaging (NNOX) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
Nano-X Imaging (NNOX) has reported Net Income towards Common Stockholders for 8 consecutive years, with -$14.1 million the latest figure, recorded in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 5.23% year-over-year to -$14.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$79.3 million (down 43.63% YoY) and the FY2025 annual result came in at -$27.3 million, down 86.71% from the prior year.
- Net Income towards Common Stockholders climbed to -$14.1 million in Q1 2026 per NNOX's latest filing, from -$36.8 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for NNOX reached as high as -$10.4 million in Q4 2023 and fell as low as -$54.9 million in Q4 2022.
- A 5-year average of -$19.4 million and a median of -$14.2 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders soared 81.05% — and 2025, when it sank 157.99%.
- Year by year, Net Income towards Common Stockholders stood at -$54.9 million in 2022, then surged by 81.05% to -$10.4 million in 2023, then tumbled by 36.93% to -$14.2 million in 2024, then plunged by 157.99% to -$36.8 million in 2025, then surged by 61.61% to -$14.1 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$14.1 million, -$36.8 million, and -$13.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Nano-X Imaging | 62,810.26 | -44.16 Mn | -2.59 Mn | -14.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.11 Mn |
| Dec 31, 2025 | -36.76 Mn |
| Sep 30, 2025 | -13.87 Mn |
| Jun 30, 2025 | -14.56 Mn |
| Mar 31, 2025 | -13.41 Mn |
| Dec 31, 2024 | -14.25 Mn |
| Sep 30, 2024 | -13.83 Mn |
| Jun 30, 2024 | -13.73 Mn |
| Mar 31, 2024 | -12.43 Mn |
| Dec 31, 2023 | -10.41 Mn |
| Sep 30, 2023 | -21.56 Mn |
| Jun 30, 2023 | -17.54 Mn |
| Mar 31, 2023 | -11.95 Mn |
| Dec 31, 2022 | -54.90 Mn |
| Sep 30, 2022 | -19.92 Mn |
| Jun 30, 2022 | -23.81 Mn |
| Mar 31, 2022 | -21.97 Mn |
| Dec 31, 2021 | -22.08 Mn |
| Sep 30, 2021 | -13.47 Mn |
| Jun 30, 2021 | -13.58 Mn |